These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27123181)

  • 1. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How does external reference pricing work in developing countries: evidence from Iran.
    Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
    Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does external reference pricing deliver what it promises? Evidence on its impact at national level.
    Kanavos P; Fontrier AM; Gill J; Efthymiadou O
    Eur J Health Econ; 2020 Feb; 21(1):129-151. PubMed ID: 31583483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International impact of external reference pricing: should national policy-makers care?
    Fontrier AM; Gill J; Kanavos P
    Eur J Health Econ; 2019 Nov; 20(8):1147-1164. PubMed ID: 31289948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in external reference pricing implementation: does it matter for public policy?
    Gill J; Fontrier AM; Kyriopoulos D; Kanavos P
    Eur J Health Econ; 2019 Dec; 20(9):1375-1397. PubMed ID: 31444673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in external price referencing in Europe: a descriptive overview.
    Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
    Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
    Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
    Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation.
    Vogler S; Schneider P; Lepuschütz L
    Cost Eff Resour Alloc; 2020 Nov; 18(1):51. PubMed ID: 33292293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of external reference pricing on pharmaceutical costs and market dynamics.
    Voehler D; Koethe BC; Synnott PG; Ollendorf DA
    Health Policy Open; 2023 Dec; 4():100093. PubMed ID: 37383884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
    Vogler S; Habl C; Bogut M; Voncina L
    Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview.
    Verghese NR; Barrenetxea J; Bhargava Y; Agrawal S; Finkelstein EA
    J Mark Access Health Policy; 2019; 7(1):1601060. PubMed ID: 31007877
    [No Abstract]   [Full Text] [Related]  

  • 19. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.